A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470

Inclusion Criteria for T1DM: * T2DM more than 12 monthM * Age ≥18 and ≤70 years * Body mass index between 18.0 and 35.0 kg/m2 inclusive. * Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator. * Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for \>12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the subject must be using an acceptable contraceptive method during and for during a period of 60 days after the last dose of Study Drug. * Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject). Inclusion Criteria for T2DM: * T1DM more than 12 monthM * Age ≥18 and ≤70 years * Body mass index between 18.0 and 30.0 kg/m2 inclusive. * Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator. * Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for \>12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the subject must be using an acceptable contraceptive method during and for during a period of 60 days after the last dose of Study Drug. * Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject). Exclusion Criteria * A subject who has proliferative retinopathy or maculopathy, severe gastroparesis, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator * Recurrent major hypoglycemia or hypoglycemic unawareness or recent ketoacidosis * pregnant or lactating women * participation in an investigational study within 30 days prior to dosing * Clinically significant abnormal ECG at screening, as judged by the Investigator